Objectives: We evaluated the potential cardiac effects of in-utero exposures to antiretroviral drugs in HIV-exposed but uninfected (HEU) children.
Introduction
Prevention of mother-to-child HIV transmission (MTCT) has been a resounding public health success story. In the past 20 years, the rate of MTCT in the United States has been reduced from 26% to under 1% using potent combination antiretroviral regimens [1] [2] [3] [4] . As the use of combination antiretroviral regimens in pregnancy has increased, concerns have been raised regarding the potential risk of in-utero combination antiretroviral exposure on long-term outcomes among HIV-exposed but uninfected (HEU) children, including mitochondrial toxicity, which has also been associated with cardiomyopathy in HIV-unexposed children [5] [6] [7] [8] [9] [10] [11] [12] .
Among HIV-infected children, cardiomyopathy was common prior to widespread use of combination antiretroviral therapy and was associated with high mortality [13] . However, a study of both HEU and HIV-infected children in the National Heart, Lung, and Blood Institute (NHLBI) Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study (P 2 C 2 ), born between 1990 and 1994, found no association between perinatal exposure to zidovudine (ZDV) monotherapy and abnormalities of left ventricular structure or function [14] . In another study, compared to the subset of antiretroviral therapyunexposed HEU children in the P 2 C 2 study, 136 children (96% exposed to combination antiretroviral therapy in utero) born between 2003 and 2006 in the NHLBIfunded Cardiovascular Status of HAART in HIV-Exposed Infants and Children cohort study (CHAART I) had significantly lower left ventricular mass, septal thickness, and left ventricular diameter, and higher left ventricular contractility at age 2 years [15] .
Because these prior studies were limited by their small sample size and/or they were conducted during an earlier era when there were fewer antiretroviral options compared to the contemporary era, which has more robust combination antiretroviral therapy options, we evaluated the relationship between perinatal antiretroviral drug exposure and echocardiographic measurements from the Pediatric HIV/AIDS Cohort Study (PHACS) Surveillance Monitoring for ART Toxicities (SMARTT) study.
Methods

Study population
The PHACS SMARTT study is a prospective cohort study designed to identify adverse effects of in-utero antiretroviral exposures on HEU children at 22 US pediatric HIV clinical centers. A reference cohort of children born to HIV-uninfected mothers was enrolled from the same study sites. The SMARTT protocol was reviewed and approved by the institutional review boards (IRBs) at all participating clinical sites and the PHACS Data and Operations Center at the Harvard School of Public Health. Written informed consent was obtained from the children's parent or legal guardian, and minor assent per site IRB requirements.
Maternal antiretroviral regimen and substance use (illicit drugs, alcohol, and tobacco) by trimester were collected at study entry or from participation in previous studies including the PACTG 219C study [11] and the Women and Infant Transmission Study [4] . After enrollment, annual SMARTT child study visits included physical exams and collection of new diagnoses and caregiver information.
Study echocardiograms
To achieve appropriate statistical power in addressing our scientific question, we determined that we needed to perform a single echocardiogram on 400 HEU children in the SMARTT cohort at the first study visit between age 3 and 5 years. All site sonographers received specific protocol training. Using two-dimensional and M-mode echocardiography, measures of cardiac function (left ventricular ejection fraction, fractional shortening, and stress-velocity index) and structural parameters (left ventricular end-diastolic short-axis dimension, posterior wall thickness, septal thickness, left ventricular mass, and thickness-to-dimension ratio, and end-systolic wall stress) were measured. All digitized echocardiograms were assessed for image quality and were centrally measured at the PHACS echocardiographic core laboratory at Boston Children's Hospital (S.D.C.). The echocardiographic core laboratory was blinded to patient, prior therapy, and echocardiographic measurements performed at the study centers. The HIV-unexposed reference cohort underwent a single echocardiogram at age 3-5 years. The only exclusion criterion for this analysis was presence of a significant congenital heart defect [2 (2%) children excluded from the HIV-unexposed reference cohort and 11 (2.7%) from the HEU cohort]. All echocardiographic parameters were expressed as Z-scores to adjust for variation in age and body surface area in the cohorts. The Z-scores for both SMARTT cohorts were calculated using normative data from a healthy pediatric reference cohort from the echocardiography laboratory at Boston Children's Hospital (BCH). The designation of 'healthy' was determined by a detailed clinical evaluation and medical record review 1 year after the echocardiographic evaluation. The BCH reference cohort was more likely to be non-Hispanic white and may not have been from the same socioeconomic strata as the SMARTT cohorts [16] . characteristics including substance use during pregnancy, age at delivery, and HIV viral load and CD4 þ cell count prior to delivery were considered as potential confounders (Table 1) . Combination antiretroviral therapy was defined as the use of at least three antiretroviral drugs. We also evaluated the subset of combination antiretroviral regimens defined as HAART (at least three antiretroviral drugs from at least two drug classes), but results were similar to those of combination antiretroviral regimens and are not presented here. Intrauterine exposures to individual antiretroviral drugs, antiretroviral drug class, and combination antiretroviral regimens were examined overall and by first-trimester exposure as this is the most critical period of cardiac development. Antiretroviral drug classes included nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and protease inhibitors.
The SMARTT HEU cohort echocardiographic parameters were descriptively compared to results from HEU children enrolled in the prior P 2 C 2 HIV study (1990) (1991) (1992) (1993) (1994) , which serves as a combination antiretroviral-unexposed historical comparison group, and the CHAART I study (2003) (2004) (2005) (2006) , which serves as a comparable combination antiretroviral-exposed group to the SMARTT cohort from an earlier antiretroviral treatment era. In the P 2 C 2 cohort, 34% were exposed to ZDV and the rest were unexposed to antiretroviral drugs. In the CHAART I cohort, 96% were exposed to combination antiretroviral therapy. Detailed methods of these studies have been previously published [17, 18] . All P 2 C 2 and CHAART I echocardiograms were also centrally remeasured at the PHACS echocardiographic core laboratory. Access to the P 2 C 2 and CHAART I databases was provided via interinstitutional data use agreements between the University of Miami, Clinical Trials and Survey Corporation (Owings Mills, Maryland, USA) and the Harvard School of Public Health.
Statistical analysis
The Z-scores of the echocardiographic parameters were summarized by HIV-exposure status and compared between the HEU and the HIV-unexposed groups using unadjusted and adjusted linear regression models. Among those in the HEU cohort with detailed information on maternal antiretroviral exposure, unadjusted linearregression models were first used to assess associations between these Z-scores and in-utero antiretroviral exposures. For each echocardiographic parameter, a core model of potential confounders (child demographic variables and maternal factors) was built using a backward selection procedure including variables with a P value less than 0.20 in the univariable models. Pregnancy outcomes (e.g. low birth weight, preterm delivery) were not considered for the selection procedure due to concerns Cardiac effects in HIV-exposed children Lipshultz et al. 93 cpm, copies per milliliter; HEU, HIV-exposed but uninfected; SMARTT, Surveillance Monitoring for ART Toxicities; VL, viral load. a Data on certain characteristics were unavailable for reference and HEU children, for ethnicity (n ¼ 0 and 1), birth weight (n ¼ 5 and 0), gestational age (n ¼ 6 and 2), small for gestational age (n ¼ 12 and 17), maternal age (n ¼ 7 and 0), substance use (n ¼ 9 and 32), and for HEU, maternal VL (n ¼ 22) and CD4 þ (n ¼ 25 that they may be on the causal pathway between in-utero antiretroviral exposure and echocardiographic outcomes. All covariates with a P value less than 0.15 were retained as part of the core model of potential confounders. Linear regression models were then fit to assess the association between in-utero antiretroviral exposures and echocardiographic Z-scores, adjusting for the core model covariates. In a sensitivity analysis, the models were restricted to children with combination antiretroviral exposure as opposed to any antiretroviral exposure. Finally, the Z-scores of selected echocardiographic parameters from the P 2 C 2 and CHAART studies were summarized and displayed graphically, along with those from the SMARTT cohorts.
Since SMARTT is a drug safety study, we prioritized limiting type II statistical errors (falsely missing a safety signal) rather than type I errors (falsely rejecting the null hypothesis) and thus no adjustments for multiple testing were used [19] [20] [21] [22] . Statistical analyses were conducted using SAS Version 9.2 (SAS Institute, Cary, North Carolina, USA) using data submitted as of April 2012, and two-sided P values 0.05 or less were considered statistically significant.
Results
Between 2007 and 2012, 428 (74%) HEU and 100 (100%) HIV-unexposed children had an echocardiogram performed, meeting the study's target sample sizes for echocardiograms. After excluding children with a congenital cardiac malformation, child and maternal characteristics are compared between the remaining 417 SMARTT HEU and 98 HIV-unexposed children in Table 1 . The two groups were generally similar with the following exceptions: the mothers in the HIV-unexposed reference cohort were younger at parturition and had a trend for lower rate of preterm delivery and for less often reported tobacco use during pregnancy compared to mothers in the HEU cohort; the HIV-unexposed children were leaner and less likely Hispanic compared to the HEU children.
A comparison of select echocardiographic Z-scores between the SMARTT HEU and HIV-unexposed reference cohorts, and the CHAART I and P 2 C 2 HEU children, is shown in Fig. 1 . The P 2 C 2 HEU cohort had markedly lower left ventricular function (left ventricular shortening fraction and stress-velocity index Z-scores) and a much greater septal thickness compared to the other three groups. There were no significant differences in mean Z-scores between the SMARTT HEU and HIV-unexposed cohorts for any echocardiographic parameter ( Table 2 and Fig. 1 ), whether with or without adjustment for characteristics which differed between the two cohorts.
All further results are limited to the 411 SMARTT HEU participants with information on timing of maternal antiretroviral exposure. Mean echocardiographic Z-scores for SMARTT, CHAART, and P 2 C 2 cohorts Mean Z-score and 95% CIs Fig. 1 . Echocardiographic Z-score comparisons between the SMARTT HIV-exposed uninfected (SMARTT HEU) and HIVunexposed (SMARTT HIV-unexposed) cohorts, and results from the previous NHLBI-funded CHAART and P 2 C 2 studies. CHAART, Cardiovascular Status of HAART in HIV-Exposed Infants and Children; CI, confidence interval; ED, end-diastolic; ES, end-systolic; HEU, HIV-exposed but uninfected; LV, left ventricular; NHLBI, National Heart, Lung, and Blood Institute; P 2 C 2 , Pediatric Pulmonary and Cardiac Complications of Vertically Transmitted HIV Infection Study; SMARTT, Surveillance Monitoring for ART Toxicities.
Left ventricular function measures
Among the SMARTT HEU participants, there were no statistically significant adjusted mean differences in Z-scores for the three measures of left ventricular function (fractional shortening, ejection fraction, and stress-velocity index) when those exposed anytime during pregnancy to a specific antiretroviral regimen or individual antiretroviral drugs were compared to those unexposed to that antiretroviral regimen or specific antiretroviral drug (Table 3) . However, first-trimester exposures to combination antiretroviral drugs tenofovir, emtricitabine, or lopinavir/ritonavir were each associated with significantly lower mean left ventricular stressvelocity index Z-scores (a load-independent measure of left ventricular contractility [23] ) compared to those not exposed to these regimens or individual antiretroviral drugs, with mean decreases of 0.22-0.40 SDs.
Structural left ventricular measures
Exposure to combination antiretroviral therapy, both overall and during the first trimester, was associated with lower left ventricular dimension Z-scores (Table 4 ). Firsttrimester, but not overall, exposures to combination antiretroviral therapy were also associated with higher mean left ventricular posterior wall thickness and mean thickness-to-dimension ratio Z-scores. Exposure to abacavir at any time during pregnancy was significantly associated with a lower mean left ventricular dimension and a higher mean left ventricular thickness-to-dimension ratio compared to those not exposed to abacavir. Exposure to atazanavir, both overall and in the first trimester, was associated with a higher mean left ventricular posterior wall thickness Z-score, whereas overall exposure to nelfinavir or lopinavir/ritonavir was associated with lower mean left ventricular posterior wall thickness Z-scores. First-trimester exposure to nevirapine was associated with higher mean left ventricular posterior wall thickness and mass Z-scores compared to children not exposed in utero to nevirapine.
The results of a sensitivity analysis limited to children with in-utero exposure to combination antiretroviral therapy (95% of the SMARTT HEU cohort) were generally similar to those of the original analysis with two exceptions: overall ZDV exposure was associated with a significantly higher mean left ventricular stress-velocity index Z-score in the sensitivity analysis (P ¼ 0.022), but not in the original analysis (P ¼ 0.10); and overall exposure to abacavir was not significantly associated with the left ventricular dimension Z-score in the sensitivity analysis (P ¼ 0.09), although it was in the original analysis (P ¼ 0.041).
In addition to the associations of echocardiographic Z-scores with in-utero antiretroviral exposures, we also observed several maternal and fetal factors that were independently associated with echocardiographic measures among the HEU cohort. Tobacco use and alcohol use during pregnancy were both associated with significant decreases in the left ventricular ejection fraction Z-score. Tobacco use during pregnancy was also associated with a 0.23 mean decrease in left ventricular fractional shortening Z-score (P ¼ 0.034).
Both tobacco use and alcohol use during pregnancy were associated with higher septal thickness Z-score (P ¼ 0.032 and P ¼ 0.019, respectively), and maternal alcohol use was associated with a 0.51 increase in mean left ventricular mass Z-score (P ¼ 0.004). In contrast, there was no association observed between echocardiographic parameters and any pregnancy outcomes, maternal age at delivery, or maternal health status as reflected by CD4 þ and viral load measurements prior to delivery. Girls had significantly lower left ventricular ejection fraction (adjusted mean difference vs. boys ¼ À0.15, P ¼ 0.040) and significantly lower mean Z-scores for several structural parameters (left ventricular dimension, posterior wall thickness, septal thickness, and mass). White and Hispanic children had significantly higher mean Z-scores for left ventricular dimension as compared to non-white and non-Hispanic children, respectively.
Discussion
We found no evidence of clinically significant cardiac toxicity associated with perinatal antiretroviral exposure among HEU children 3-5 years of age. There were no statistically significant differences between the HEU (95% exposed to combination antiretroviral therapy) and the HIV-unexposed SMARTT cohorts in mean Z-scores for any echocardiographic parameter. However, we did observe some associations between specific antiretroviral exposures and certain echocardiographic parameters within the HEU cohort. Whereas the overall cardiac function of the HEU children was similar to that of the SMARTT HIV-unexposed cohort, there was significant variability within the HEU cohort in echocardiographic Z-scores which could be at least partially explained by the antiretroviral exposures. Both the SMARTT HEU and HIV-unexposed cohorts differed from the BCH reference cohort's mean Z-scores of zero for some parameters. This observation may reflect the effects of differences between the SMARTT cohorts and the BCH reference cohort for factors such as race ethnicity, income and education level, nutritional status, environmental exposures, and other demographic and lifestyle characteristics. However, these differences would be unlikely to affect our observed associations of echocardiographic parameters with certain early prenatal combination antiretroviral exposures in the HEU group.
As noted above, certain antiretroviral exposures were associated with differences in mean Z-scores for echocardiographic parameters within the HEU group. We found significantly lower left ventricular stress-velocity index (a load-independent measure of the left ventricular function) in HEU children exposed in the first trimester 96 AIDS 2015, Vol 29 No 1 Table 3 . Adjusted differences in functional echocardiographic parameter mean Z-scores for 411 HIV-exposed uninfected children in SMARTT exposed vs. unexposed in utero to specific antiretroviral regimens or drugs. Each echocardiographic parameter was modeled separately in an adjusted linear regression model comparing those with the exposure of interest to unexposed (to that antiretroviral regimen or drug), with adjustment for covariates as follows: mother's use of illicit drugs during pregnancy and child's sex (left ventricular ejection fraction); child's race and mother's use of illicit drugs during pregnancy (left ventricular fractional shortening); age at echo, mother's use of alcohol during pregnancy, and child's BMI (left ventricular stress-velocity index). Table 4 . Adjusted differences in structural echocardiographic parameter mean Z-scores with at least marginal significance for 411 HIV-exposed uninfected children in SMARTT exposed vs.
unexposed in utero to specific antiretroviral regimens or drugs. Each echocardiographic parameter was modeled separately in an adjusted linear regression model comparing those with the exposure of interest to unexposed (to that antiretroviral regimen or drug), with adjustment for covariates as follows: child's race, child's sex, child's BMI, and mother's age at delivery (left ventricular short axis dimension); mother's alcohol use during pregnancy (left ventricular posterior wall thickness); mother's alcohol use during pregnancy and child's sex (septal thickness); maternal alcohol use during pregnancy, child's sex and child's BMI (left ventricular mass); age at echo, child's sex, and mother's age at delivery (left ventricular wall stress); child's race, mother's alcohol use during pregnancy and child's BMI (left ventricular thickness-to-dimension ratio).
to combination antiretroviral drugs and specific NRTIs (tenofovir, emtricitabine) or lopinavir/ritonavir, compared to HEU children not exposed to combination antiretroviral drugs or these specific agents. Exposure to combination antiretroviral drugs and specific NRTI and protease inhibitor agents anytime during pregnancy was generally associated with lower left ventricular dimension than lack of exposure to these regimens or agents, although this does not necessarily reflect a lower left ventricular dimension than expected in comparison to the BCH reference cohort. Because the number of cardiac myocytes is fixed at birth, a small left ventricle (LV) is a potential concern regarding the ability of the LV to meet the increased cardiovascular demands as these children grow into adulthood. Only longitudinal cardiac reassessment of this population can address this concern. First-trimester exposures to combination antiretroviral regimens and to specific agents from all three antiretroviral drug classes were associated with higher left ventricular posterior wall thickness. All of the differences in Z-scores were less than 1 SD, and most were less than 0.5 SD. Differences in echocardiographic Z-scores greater than 2 SD are typically considered pathologic, but the potential clinical significance of the smaller changes we observed are unknown.
The current findings of slightly lower left ventricular function, lower dimension, and higher posterior wall thickness associated with combination antiretroviral and specific antiretroviral exposures, compared to children unexposed to combination antiretroviral therapy or these specific antiretroviral drugs, could be consistent with a subclinical inflammatory response characterized by injury or death of cardiac myocytes along with an inflammatory infiltrate in the left ventricular posterior wall and interventricular septum. These findings are found in other inflammatory heart conditions such as myocarditis [24] [25] [26] . These conclusions are further supported by a previous evaluation of cardiac and inflammatory biomarkers in the same SMARTT study population which could be consistent with a myocardial inflammatory process [27] . Since almost all mothers received antiretroviral drugs during pregnancy, the relative contributions to a possible inflammatory response of prenatal exposure to antiretroviral drugs vs. maternal HIV cannot be addressed in this analysis. Future studies of cardiac biomarkers may help identify HEU children who require further cardiac evaluation including echocardiography. Innate immune activation has been proposed as one of the reasons for the increased cardiovascular risk and mortality seen in HIVinfected adults receiving long-term antiretroviral therapy [28] [29] [30] [31] .
We also found that maternal alcohol use and tobacco use during pregnancy were both associated with lower left ventricular function, as well as higher septal thickness and left ventricular mass, independent of the observed antiretroviral associations. Maternal alcohol use during pregnancy has been associated with structural cardiac defects, long QT syndrome (a potential risk for sudden cardiac death), and heart muscle disease in both human and animal studies [32] [33] [34] [35] [36] [37] . Prenatal tobacco exposure has been associated with inhibition of cardiac DNA synthesis, impaired vascular smooth muscle structure and function, and structural cardiac defects [37] .
A descriptive comparison of the SMARTT cohort with the earlier CHAART I and P 2 C 2 HEU studies showed echocardiographic findings which were generally consistent for the SMARTTand previous CHAART I studies (both conducted in the combination antiretroviral era) in terms of direction, although not always of the same magnitude. Echocardiographic findings were generally more extreme in the P 2 C 2 HEU cohort and sometimes in the opposite direction, compared to the SMARTT and CHAART I cohorts, but these differences were not consistent across all echocardiographic parameters. The P 2 C 2 HEU cohort was either antiretroviral-unexposed or only ZDV-exposed in the perinatal period, and generally had more extreme changes in echocardiographic parameters. This suggests that the combination antiretroviral regimens taken by mothers in the SMARTT and CHAART I cohorts and the resulting decrease in maternal viral load or inflammatory mediators led not only to a marked reduction in MTCTof HIV but also to a healthier echocardiographic profile at age 3-5 years. However, there could be differences in noncombination antiretroviral exposures in the SMARTTand CHAART I mothers, such as maternal health, lifestyle, or environmental exposures, compared to the P 2 C 2 HEU mothers, which could contribute to the healthier echocardiographic profile in their young HEU children.
In the SMARTT study, we found lower Z-scores for several echocardiographic parameters in girls compared to boys. In the CHAART I study, differences in several echocardiographic measures were greater in girls, as opposed to boys, when compared to the P 2 C 2 comparison group [15] . In healthy children, there are no sex differences in echocardiographic Z-scores. The reason for these sex differences in echocardiographic measures in HEU children in the SMARTT and CHAART I studies is not clear.
Study limitations include that a single echocardiographic assessment per child does not allow evaluation of the trajectory or persistence of any cardiac changes associated with antiretroviral exposures. This study design cannot differentiate between potential cardiac effects of perinatal exposure to HIV and perinatal exposure to specific antiretroviral agents. Our comparison of the SMARTT and CHAART I antiretroviral-exposed cohorts to the P 2 C 2 antiretroviral-unexposed cohort suggests that potential cardiac effects of perinatal antiretroviral exposure in the combination antiretroviral era are less extreme than in the precombination antiretroviral era.
Alternatively, this may indicate that poorer HIV control in precombination antiretroviral era mothers could explain the cardiac effect differences instead of, or in addition to, any antiretroviral effects. Finally, the current analysis utilized an initial 'predictive' screening analysis which is appropriate to identify potential safety signals, but cannot evaluate causal relationships. However, the large number of participants and inclusion of both internal (SMARTT HIV-unexposed) and external (Boston Children's Hospital) comparison groups are key strengths of this study, although the BCH reference cohort differed in terms of racial distribution and possibly socioeconomic status from both the HEU and HIVunexposed cohorts. The analyses were adjusted for known potential confounders. However, there is still the possibility of residual confounding from unmeasured covariates. Finally, since the SMARTT study was primarily a safety study, we did not adjust for multiple comparisons to minimize type II errors. Due to the large number of comparisons, some associations could be due to chance, and findings should be confirmed in further studies.
We found no evidence of clinically significant cardiac toxicity associated with perinatal antiretroviral (mostly combination antiretroviral) exposure in HEU children at 3-5 years of age compared to a demographically similar reference cohort of HIV-unexposed and apparently healthy children. However, the associations of subclinical differences in left ventricular structure and function with specific in-utero antiretroviral exposures, particularly in the first trimester, suggest that these children should be longitudinally studied to determine if long-term deleterious cardiac effects emerge as they age. Such follow-up studies could inform the selection of optimal antiretroviral regimens in pregnancy that will simultaneously prevent perinatal transmission of HIV and optimize long-term cardiac health in infants born to HIV-infected mothers.
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